These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
523 related articles for article (PubMed ID: 24439479)
1. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479 [TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
3. Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects. Osorio RS; Ducca EL; Wohlleber ME; Tanzi EB; Gumb T; Twumasi A; Tweardy S; Lewis C; Fischer E; Koushyk V; Cuartero-Toledo M; Sheikh MO; Pirraglia E; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Schuetz S; Varga AW; Ayappa I; Rapoport DM; de Leon MJ Sleep; 2016 Jun; 39(6):1253-60. PubMed ID: 26951396 [TBL] [Abstract][Full Text] [Related]
4. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
5. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network. Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102 [TBL] [Abstract][Full Text] [Related]
6. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
7. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550 [TBL] [Abstract][Full Text] [Related]
8. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
10. Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS). Saunders TS; Jenkins N; Blennow K; Ritchie C; Muniz-Terrera G EBioMedicine; 2022 Sep; 83():104241. PubMed ID: 36041266 [TBL] [Abstract][Full Text] [Related]
11. Imaging and cerebrospinal fluid biomarkers in the search for Alzheimer's disease mechanisms. Osorio RS; Pirraglia E; Gumb T; Mantua J; Ayappa I; Williams S; Mosconi L; Glodzik L; de Leon MJ Neurodegener Dis; 2014; 13(2-3):163-5. PubMed ID: 24107601 [TBL] [Abstract][Full Text] [Related]
12. Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer's disease patients with the APOE4 genotype. Motta C; Assogna M; Bonomi CG; Mascolo AP; De Lucia V; Semprini R; Mercuri NB; Koch G; Martorana A Eur J Neurol; 2021 Dec; 28(12):3965-3971. PubMed ID: 34309155 [TBL] [Abstract][Full Text] [Related]
13. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185 [TBL] [Abstract][Full Text] [Related]
14. A data-driven model of biomarker changes in sporadic Alzheimer's disease. Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC; Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224 [TBL] [Abstract][Full Text] [Related]
15. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Morris JC; Roe CM; Xiong C; Fagan AM; Goate AM; Holtzman DM; Mintun MA Ann Neurol; 2010 Jan; 67(1):122-31. PubMed ID: 20186853 [TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Alzheimer's Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment. Sun Y; Moghekar A; Soldan A; Pettigrew C; Greenberg B; Albert M; Wang MC; J Alzheimers Dis; 2023; 96(1):287-300. PubMed ID: 37742656 [TBL] [Abstract][Full Text] [Related]
18. Assessment of apolipoprotein E genotype for β-amyloid status prediction. Peña-Bautista C; Álvarez-Sánchez L; García L; Baquero M; Cháfer-Pericás C Curr Alzheimer Res; 2021; 18(13):1032-1040. PubMed ID: 34951383 [TBL] [Abstract][Full Text] [Related]
19. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805 [TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ; Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]